ACTIV 6

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: DANIEL K. BENJAMIN
Organization: DUKE UNIVERSITY
Fiscal Year: 2021
Award: $38,494,599
Funding agency: National Center for Advancing Translational Sciences

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus that first emerged
in December 2019 and has since caused a global pandemic unseen in almost a century with respect to the
number of cases and overall mortality. Over 2020, advances were made for treatment of COVID-19 and
several vaccinations have received emergency use authorization for prevention of SARS-CoV-2 infections.
However, the pandemic continues to evolve with new variants and surges of infections in different regions of
the world, requiring an ongoing evidence-generating platform, in particular for the oral treatment of COVID-19
infection in the outpatient setting. To address this unmet need the Duke Clinical Research Institute, Vanderbilt
University Medical Center and partners are coming together to coordinate ACTIV-6 as a platform with a master
clinical trial protocol that can serve as an evidence generating system for prioritized drugs repurposed from
other indications with an established safety record and preliminary evidence of clinical efficacy for the
treatment of COVID-19.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Academic Medical Centers><Accident and Emergency department><Address><Affect><Ambulatory Care><Benefits and Risks><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 diagnosis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19><COVID19 crisis><COVID19 diagnosis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Clinical><Clinical Data><Clinical Investigator><Clinical Research><Clinical Study><Clinical Trial Protocol><Clinical Trials><Clinical trial protocol document><CoV-2><CoV2><Collaborations><Data><Data Coordinating Center><Data Coordination Center><Data Science><Data Scientist><Early treatment><Emergency Department><Emergency room><Enrollment><Ensure><FDA EUA><FDA Emergency Use Authorization><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Generations><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><Goals><Health Care Systems><Healthcare Systems><Hospitals><Hybrids><Infection><Informatics><International><Investigators><Leadership><Link><Methodology><Methods><Oral><Out-patients><Outpatient Care><Outpatients><Participant><Patients><Pragmatic clinical trial><Prevention><Principal Investigator><Protocol><Protocols documentation><Research><Research Institute><Research Personnel><Researchers><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 diagnosis><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Site><Special Population><System><United States><University Medical Centers><Vaccination><Variant><Variation><Wuhan coronavirus><beta CoV><beta coronavirus><betaCoV><betacoronavirus><clinical efficacy><cohort><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 diagnosis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><data management><design><designing><diagnosed with COVID-19><diagnosed with COVID19><diagnosed with SARS-CoV-2><diagnosed with coronavirus 2019><diagnosed with coronavirus disease 2019><drug repurposing><early therapy><emergency use authorization><enroll><experience><geographic site><hCoV19><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><mortality><nCoV2><non-drug><nondrug><novel><operation><outpatient treatment><pandemic><pandemic disease><participant engagement><patient engagement><repurposing agent><repurposing medication><response><severe acute respiratory syndrome coronavirus 2 diagnosis><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><statistics><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><β CoV><β coronavirus><βCoV>